Immunome Inc. (NASDAQ: IMNM)

Immunome Inc. (IMNM) is a biopharmaceutical company that operates in the development of targeted oncology therapies. The company's primary business activities involve the discovery and development of novel or underexplored targets, with the aim of establishing a broad pipeline of preclinical and clinical assets. Immunome's pipeline consists of one clinical and three preclinical assets, including AL102, IM-1021, IM-3050, and IM-4320.

Immunome's main business activities include the discovery and development of novel or underexplored targets in oncology. The company operates in the biopharmaceutical industry, focusing on the development of targeted therapies to treat cancer. Immunome's business activities span across the discovery and development stages of its assets, aiming to establish a broad pipeline of preclinical and clinical assets. The company's headquarters are in New Jersey, USA, and it operates within the country and internationally.

Immunome generates revenue through its business model, which is built around its expertise in discovering and developing targeted therapies, as well as its ability to evaluate and acquire high-potential assets. The company's primary products and services include its proprietary discovery platform, which uses a patient-derived approach to identify cancer-associated targets, and its pipeline of preclinical and clinical assets. Immunome's revenue is generated primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company has a strong balance sheet, with a significant amount of cash and investments.

Immunome operates in a highly competitive industry, with many established players and a large number of new entrants. However, the company believes that its focus on targeted oncology therapies, combined with its expertise in discovering and developing novel or underexplored targets, will enable it to differentiate itself from its competitors and establish a strong position in the market. Some of Immunome's competitors include AbCellera Biologics, Adaptive Biotechnologies, AIMM Therapeutics, IGM Biosciences, and OncoReponse, among others. Additionally, the company competes with large, multinational pharmaceutical companies, such as Immunogen, AstraZeneca, Amgen, Bayer AG, BMS, Eli Lilly and Company, Genentech, Merck& Co. Inc., Novartis, Seagen, and Johnson& Johnson.

Immunome's customers are primarily pharmaceutical companies and research institutions that are interested in acquiring its assets or partnering with the company to develop new therapies. The company has a number of partnerships and collaborations in place, including a license agreement with Zentalis Pharmaceuticals for the development of IM-1021.

AL102 is an investigational gamma secretase inhibitor currently under evaluation in a Phase 3 trial for the treatment of desmoid tumors. Desmoid tumors are a rare and aggressive type of soft tissue cancer that can occur in various parts of the body. AL102 is designed to inhibit the Notch pathway, which is involved in the development and progression of cancer.

IM-1021 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate (ADC) targeting ROR1-expressing solid tumors and lymphomas. ROR1 is an oncofetal protein that is expressed in a variety of solid tumors and lymphomas, making it an attractive target for cancer therapy. IM-1021 is designed to deliver a cytotoxic payload directly to ROR1-expressing cells, where it can induce apoptosis and inhibit tumor growth.

IM-3050 is a fibroblast activation protein (FAP) targeted radioligand therapy (RLT) for the treatment of solid tumors. FAP is a membrane-bound serine protease that is overexpressed in many types of cancer, making it a promising target for cancer therapy. IM-3050 is designed to deliver a radionuclide directly to FAP-expressing cells, where it can induce apoptosis and inhibit tumor growth.

IM-4320 is an anti-interleukin-38 (IL-38) immunotherapy candidate. IL-38 is an immunosuppressive cytokine that is overexpressed in many types of cancer, making it a potential target for cancer therapy. IM-4320 is designed to target IL-38-expressing cells and induce an immune response against cancer.